Cargando…

Prediction of "hot spots" of aggregation in disease-linked polypeptides

BACKGROUND: The polypeptides involved in amyloidogenesis may be globular proteins with a defined 3D-structure or natively unfolded proteins. The first class includes polypeptides such as β2-microglobulin, lysozyme, transthyretin or the prion protein, whereas β-amyloid peptide, amylin or α-synuclein...

Descripción completa

Detalles Bibliográficos
Autores principales: de Groot, Natalia Sánchez, Pallarés, Irantzu, Avilés, Francesc X, Vendrell, Josep, Ventura, Salvador
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1262731/
https://www.ncbi.nlm.nih.gov/pubmed/16197548
http://dx.doi.org/10.1186/1472-6807-5-18
_version_ 1782125893644189696
author de Groot, Natalia Sánchez
Pallarés, Irantzu
Avilés, Francesc X
Vendrell, Josep
Ventura, Salvador
author_facet de Groot, Natalia Sánchez
Pallarés, Irantzu
Avilés, Francesc X
Vendrell, Josep
Ventura, Salvador
author_sort de Groot, Natalia Sánchez
collection PubMed
description BACKGROUND: The polypeptides involved in amyloidogenesis may be globular proteins with a defined 3D-structure or natively unfolded proteins. The first class includes polypeptides such as β2-microglobulin, lysozyme, transthyretin or the prion protein, whereas β-amyloid peptide, amylin or α-synuclein all belong to the second class. Recent studies suggest that specific regions in the proteins act as "hot spots" driving aggregation. This should be especially relevant for natively unfolded proteins or unfolded states of globular proteins as they lack significant secondary and tertiary structure and specific intra-chain interactions that can mask these aggregation-prone regions. Prediction of such sequence stretches is important since they are potential therapeutic targets. RESULTS: In this study we exploited the experimental data obtained in an in vivo system using β-amyloid peptide as a model to derive the individual aggregation propensities of natural amino acids. These data are used to generate aggregation profiles for different disease-related polypeptides. The approach detects the presence of "hot spots" which have been already validated experimentally in the literature and provides insights into the effect of disease-linked mutations in these polypeptides. CONCLUSION: The proposed method might become a useful tool for the future development of sequence-targeted anti-aggregation pharmaceuticals.
format Text
id pubmed-1262731
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-12627312005-10-22 Prediction of "hot spots" of aggregation in disease-linked polypeptides de Groot, Natalia Sánchez Pallarés, Irantzu Avilés, Francesc X Vendrell, Josep Ventura, Salvador BMC Struct Biol Research Article BACKGROUND: The polypeptides involved in amyloidogenesis may be globular proteins with a defined 3D-structure or natively unfolded proteins. The first class includes polypeptides such as β2-microglobulin, lysozyme, transthyretin or the prion protein, whereas β-amyloid peptide, amylin or α-synuclein all belong to the second class. Recent studies suggest that specific regions in the proteins act as "hot spots" driving aggregation. This should be especially relevant for natively unfolded proteins or unfolded states of globular proteins as they lack significant secondary and tertiary structure and specific intra-chain interactions that can mask these aggregation-prone regions. Prediction of such sequence stretches is important since they are potential therapeutic targets. RESULTS: In this study we exploited the experimental data obtained in an in vivo system using β-amyloid peptide as a model to derive the individual aggregation propensities of natural amino acids. These data are used to generate aggregation profiles for different disease-related polypeptides. The approach detects the presence of "hot spots" which have been already validated experimentally in the literature and provides insights into the effect of disease-linked mutations in these polypeptides. CONCLUSION: The proposed method might become a useful tool for the future development of sequence-targeted anti-aggregation pharmaceuticals. BioMed Central 2005-09-30 /pmc/articles/PMC1262731/ /pubmed/16197548 http://dx.doi.org/10.1186/1472-6807-5-18 Text en Copyright © 2005 de Groot et al; licensee BioMed Central Ltd.
spellingShingle Research Article
de Groot, Natalia Sánchez
Pallarés, Irantzu
Avilés, Francesc X
Vendrell, Josep
Ventura, Salvador
Prediction of "hot spots" of aggregation in disease-linked polypeptides
title Prediction of "hot spots" of aggregation in disease-linked polypeptides
title_full Prediction of "hot spots" of aggregation in disease-linked polypeptides
title_fullStr Prediction of "hot spots" of aggregation in disease-linked polypeptides
title_full_unstemmed Prediction of "hot spots" of aggregation in disease-linked polypeptides
title_short Prediction of "hot spots" of aggregation in disease-linked polypeptides
title_sort prediction of "hot spots" of aggregation in disease-linked polypeptides
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1262731/
https://www.ncbi.nlm.nih.gov/pubmed/16197548
http://dx.doi.org/10.1186/1472-6807-5-18
work_keys_str_mv AT degrootnataliasanchez predictionofhotspotsofaggregationindiseaselinkedpolypeptides
AT pallaresirantzu predictionofhotspotsofaggregationindiseaselinkedpolypeptides
AT avilesfrancescx predictionofhotspotsofaggregationindiseaselinkedpolypeptides
AT vendrelljosep predictionofhotspotsofaggregationindiseaselinkedpolypeptides
AT venturasalvador predictionofhotspotsofaggregationindiseaselinkedpolypeptides